BCRX
BUYMeanRevComposite
69.20
Technical
47.10
Fundamental
76.60
Rank
—
Price
9.07
Hurst
0.25
As of
Aug 6, 2026
Daily
BioCryst Pharmaceuticals, Inc.
HealthcareDrug Manufacturers - Specialty & GenericBioCryst Pharmaceuticals is a biotechnology company focused on treatments for hereditary angioedema and other uncommon conditions. The company currently sells peramivir injection for influenza treatment under multiple brand names and ORLADEYO, an oral medication for hereditary angioedema. BioCryst also has several drugs in development for conditions including netherton syndrome, diabetic macular edema, and atopic dermatitis, along with partnerships with pharmaceutical firms and research institutions.
Market cap
$2.2B
P/E (trailing)
—
P/E (forward)
10.27
PEG ratio
9.39
Dividend yield
0.00%
Beta
0.55
52w range
6.23 – 11.22
Return on equity
—
Profit margin
-40.90%
Revenue growth
+33.60%
Earnings growth
+1400.00%
Price history
1Y: 8.47 (+15.7%) · range 6.24–11.11
Cycle position
37/ 100 cycle scoreAPPROACHING ENTRY
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 44 · WEAK SETUP · exit proximity 0
Conviction
46/ 100 · maturity 14%
VScore.0913
Buildup.3036
EMA entry setup.3844
Fundamentals.2377
Volume profile
POC
8.37
Price vs POC
+1.2%
Overhead supply
67%
Runway
+14.6%
Value area 7.89–9.74 · 67% of 120d volume overhead · heavy supply
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| trader-sentiment | 0.462 | Oct 21, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +8.49% | +13.87% | mature |
| 40d | -12.15% | +13.87% | mature |